Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.50
MDT's Cash-to-Debt is ranked lower than
75% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. MDT: 0.50 )
Ranked among companies with meaningful Cash-to-Debt only.
MDT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 0.87 Max: No Debt
Current: 0.5
0.15
No Debt
Equity-to-Asset 0.52
MDT's Equity-to-Asset is ranked lower than
67% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MDT: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
MDT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.63 Max: 0.82
Current: 0.52
0.37
0.82
Debt-to-Equity 0.57
MDT's Debt-to-Equity is ranked lower than
71% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. MDT: 0.57 )
Ranked among companies with meaningful Debt-to-Equity only.
MDT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.32 Max: 1.43
Current: 0.57
0.02
1.43
Debt-to-EBITDA 3.13
MDT's Debt-to-EBITDA is ranked lower than
64% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. MDT: 3.13 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MDT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.47  Med: 2.03 Max: 6.63
Current: 3.13
1.47
6.63
Interest Coverage 5.61
MDT's Interest Coverage is ranked lower than
82% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 66.37 vs. MDT: 5.61 )
Ranked among companies with meaningful Interest Coverage only.
MDT' s Interest Coverage Range Over the Past 10 Years
Min: 4.3  Med: 12.09 Max: 16.44
Current: 5.61
4.3
16.44
Piotroski F-Score: 7
Altman Z-Score: 2.50
Beneish M-Score: -2.57
WACC vs ROIC
4.91%
3.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 21.12
MDT's Operating Margin % is ranked higher than
88% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. MDT: 21.12 )
Ranked among companies with meaningful Operating Margin % only.
MDT' s Operating Margin % Range Over the Past 10 Years
Min: 20.67  Med: 29.4 Max: 30.24
Current: 21.12
20.67
30.24
Net Margin % 9.44
MDT's Net Margin % is ranked higher than
74% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. MDT: 9.44 )
Ranked among companies with meaningful Net Margin % only.
MDT' s Net Margin % Range Over the Past 10 Years
Min: 9.44  Med: 17.27 Max: 22.35
Current: 9.44
9.44
22.35
ROE % 5.57
MDT's ROE % is ranked higher than
59% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. MDT: 5.57 )
Ranked among companies with meaningful ROE % only.
MDT' s ROE % Range Over the Past 10 Years
Min: 5.57  Med: 18.07 Max: 22.29
Current: 5.57
5.57
22.29
ROA % 2.88
MDT's ROA % is ranked higher than
61% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. MDT: 2.88 )
Ranked among companies with meaningful ROA % only.
MDT' s ROA % Range Over the Past 10 Years
Min: 2.88  Med: 9.65 Max: 11.99
Current: 2.88
2.88
11.99
ROC (Joel Greenblatt) % 72.83
MDT's ROC (Joel Greenblatt) % is ranked higher than
91% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. MDT: 72.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MDT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.55  Med: 67 Max: 79.17
Current: 72.83
51.55
79.17
3-Year Revenue Growth Rate 8.40
MDT's 3-Year Revenue Growth Rate is ranked higher than
63% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. MDT: 8.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MDT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.2  Med: 12.6 Max: 27
Current: 8.4
4.2
27
3-Year EBITDA Growth Rate 8.30
MDT's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. MDT: 8.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MDT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -3.7  Med: 16.5 Max: 27.1
Current: 8.3
-3.7
27.1
3-Year EPS without NRI Growth Rate -1.50
MDT's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 7.80 vs. MDT: -1.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MDT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 15.6 Max: 27.1
Current: -1.5
-9.7
27.1
» MDT's 30-Y Financials

Financials (Next Earnings Date: 2018-05-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

MDT Guru Trades in Q2 2017

Jim Simons 434,000 sh (New)
Ken Fisher 183,765 sh (+2484.96%)
Joel Greenblatt 441,394 sh (+96.26%)
HOTCHKIS & WILEY 2,227,597 sh (+80.26%)
Paul Tudor Jones 19,585 sh (+66.10%)
John Buckingham 19,727 sh (+8.54%)
Jeremy Grantham 4,372,844 sh (+3.97%)
Diamond Hill Capital 2,679,692 sh (+3.15%)
Mairs and Power 3,485,426 sh (+0.33%)
David Carlson 970,000 sh (unchged)
First Eagle Investment 1,434 sh (unchged)
NWQ Managers 3,432 sh (unchged)
Caxton Associates 6,900 sh (unchged)
Bill Nygren 2,440,000 sh (unchged)
Richard Pzena Sold Out
Ruane Cunniff Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Jeff Auxier 146,998 sh (-0.02%)
Mario Gabelli 25,670 sh (-0.74%)
T Rowe Price Equity Income Fund 2,706,600 sh (-1.58%)
Barrow, Hanley, Mewhinney & Strauss 19,685,524 sh (-2.58%)
Pioneer Investments 4,891,310 sh (-4.70%)
Dodge & Cox 11,583,871 sh (-5.15%)
Manning & Napier Advisors, Inc 5,198,146 sh (-8.24%)
PRIMECAP Management 9,868,910 sh (-11.04%)
Vanguard Health Care Fund 16,509,984 sh (-11.99%)
Robert Olstein 91,150 sh (-24.67%)
Eaton Vance Worldwide Health Sciences Fund 70,571 sh (-87.08%)
» More
Q3 2017

MDT Guru Trades in Q3 2017

Jim Simons 6,397,513 sh (+1374.08%)
Paul Tudor Jones 58,839 sh (+200.43%)
Diamond Hill Capital 3,441,700 sh (+28.44%)
Robert Olstein 111,000 sh (+21.78%)
T Rowe Price Equity Income Fund 3,100,000 sh (+14.53%)
John Buckingham 21,123 sh (+7.08%)
Dodge & Cox 12,147,095 sh (+4.86%)
Caxton Associates 7,200 sh (+4.35%)
Ken Fisher 188,912 sh (+2.80%)
Mairs and Power 3,554,055 sh (+1.97%)
Manning & Napier Advisors, Inc 5,289,068 sh (+1.75%)
Pioneer Investments 4,937,553 sh (+0.95%)
Jeff Auxier 148,248 sh (+0.85%)
Signature Select Canadian Fund 64,100 sh (+0.79%)
HOTCHKIS & WILEY 2,236,797 sh (+0.41%)
Vanguard Health Care Fund 16,509,984 sh (unchged)
David Carlson 970,000 sh (unchged)
First Eagle Investment 1,434 sh (unchged)
Bill Nygren 2,440,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 70,571 sh (unchged)
NWQ Managers 3,339 sh (-2.71%)
PRIMECAP Management 9,256,010 sh (-6.21%)
Jeremy Grantham 4,075,480 sh (-6.80%)
Mario Gabelli 23,820 sh (-7.21%)
Barrow, Hanley, Mewhinney & Strauss 16,574,247 sh (-15.80%)
Joel Greenblatt 316,892 sh (-28.21%)
» More
Q4 2017

MDT Guru Trades in Q4 2017

First Pacific Advisors 5,250 sh (New)
Ray Dalio 25,152 sh (New)
Steven Cohen 1,589,025 sh (New)
Caxton Associates 16,777 sh (+133.01%)
Dodge & Cox 18,284,758 sh (+50.53%)
Bill Nygren 3,190,000 sh (+30.74%)
Mario Gabelli 29,314 sh (+23.06%)
John Buckingham 25,150 sh (+19.06%)
Diamond Hill Capital 4,066,070 sh (+18.14%)
HOTCHKIS & WILEY 2,480,897 sh (+10.91%)
Pioneer Investments 5,324,932 sh (+7.85%)
Robert Olstein 117,000 sh (+5.41%)
Jeff Auxier 155,333 sh (+4.78%)
T Rowe Price Equity Income Fund 3,200,000 sh (+3.23%)
Mairs and Power 3,640,623 sh (+2.44%)
Jeremy Grantham 4,081,011 sh (+0.14%)
First Eagle Investment 1,434 sh (unchged)
Steven Cohen 500,000 sh (unchged)
NWQ Managers Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,698,567 sh (-5.28%)
PRIMECAP Management 8,753,098 sh (-5.43%)
Vanguard Health Care Fund 15,408,784 sh (-6.67%)
Ken Fisher 164,198 sh (-13.08%)
David Carlson 800,000 sh (-17.53%)
Paul Tudor Jones 43,331 sh (-26.36%)
Joel Greenblatt 204,272 sh (-35.54%)
Jim Simons 1,432,441 sh (-77.61%)
» More
Q1 2018

MDT Guru Trades in Q1 2018

T Rowe Price Equity Income Fund 3,320,000 sh (+3.75%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
T Rowe Price Equity Income Fund 2018-03-31 Add 3.75%0.05%$76.55 - $87.26 $ 80.02-3%3,320,000
Dodge & Cox 2017-12-31 Add 50.53%0.38%$76.93 - $83.5 $ 80.02-0%18,284,758
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -5.28%0.1%$76.93 - $83.5 $ 80.02-0%15,698,567
Vanguard Health Care Fund 2017-12-31 Reduce -6.67%0.18%$76.93 - $83.5 $ 80.02-0%15,408,784
T Rowe Price Equity Income Fund 2017-12-31 Add 3.23%0.04%$76.93 - $83.5 $ 80.02-0%3,200,000
Bill Nygren 2017-12-31 Add 30.74%0.32%$76.93 - $83.5 $ 80.02-0%3,190,000
HOTCHKIS & WILEY 2017-12-31 Add 10.91%0.07%$76.93 - $83.5 $ 80.02-0%2,480,897
Joel Greenblatt 2017-12-31 Reduce -35.54%0.13%$76.93 - $83.5 $ 80.02-0%204,272
Ken Fisher 2017-12-31 Reduce -13.08%$76.93 - $83.5 $ 80.02-0%164,198
Robert Olstein 2017-12-31 Add 5.41%0.06%$76.93 - $83.5 $ 80.02-0%117,000
Mario Gabelli 2017-12-31 Add 23.06%$76.93 - $83.5 $ 80.02-0%29,314
NWQ Managers 2017-12-31 Sold Out $76.93 - $83.5 $ 80.02-0%0
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -15.80%0.42%$77.71 - $88.9 $ 80.02-4%16,574,247
Dodge & Cox 2017-09-30 Add 4.86%0.04%$77.71 - $88.9 $ 80.02-4%12,147,095
T Rowe Price Equity Income Fund 2017-09-30 Add 14.53%0.15%$77.71 - $88.9 $ 80.02-4%3,100,000
HOTCHKIS & WILEY 2017-09-30 Add 0.41%$77.71 - $88.9 $ 80.02-4%2,236,797
Joel Greenblatt 2017-09-30 Reduce -28.21%0.16%$77.71 - $88.9 $ 80.02-4%316,892
Ken Fisher 2017-09-30 Add 2.80%$77.71 - $88.9 $ 80.02-4%188,912
Robert Olstein 2017-09-30 Add 21.78%0.2%$77.71 - $88.9 $ 80.02-4%111,000
Mario Gabelli 2017-09-30 Reduce -7.21%$77.71 - $88.9 $ 80.02-4%23,820
NWQ Managers 2017-09-30 Reduce -2.71%$77.71 - $88.9 $ 80.02-4%3,339
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -2.58%0.06%$80.01 - $89.3 $ 80.02-5%19,685,524
Vanguard Health Care Fund 2017-06-30 Reduce -11.99%0.41%$80.01 - $89.3 $ 80.02-5%16,509,984
Dodge & Cox 2017-06-30 Reduce -5.15%0.04%$80.01 - $89.3 $ 80.02-5%11,583,871
T Rowe Price Equity Income Fund 2017-06-30 Reduce -1.58%0.02%$80.01 - $89.3 $ 80.02-5%2,706,600
HOTCHKIS & WILEY 2017-06-30 Add 80.26%0.35%$80.01 - $89.3 $ 80.02-5%2,227,597
Joel Greenblatt 2017-06-30 Add 96.26%0.27%$80.01 - $89.3 $ 80.02-5%441,394
Ken Fisher 2017-06-30 Add 2484.96%0.03%$80.01 - $89.3 $ 80.02-5%183,765
Robert Olstein 2017-06-30 Reduce -24.67%0.31%$80.01 - $89.3 $ 80.02-5%91,150
Mario Gabelli 2017-06-30 Reduce -0.74%$80.01 - $89.3 $ 80.02-5%25,670
Ruane Cunniff 2017-06-30 Sold Out $80.01 - $89.3 $ 80.02-5%0
Richard Pzena 2017-06-30 Sold Out $80.01 - $89.3 $ 80.02-5%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NYSE:ABT, NYSE:SYK, NAS:ISRG, NYSE:BSX, NYSE:EW, NYSE:ZBH, NAS:ALGN, LSE:SN., NAS:ABMD, NYSE:TFX, NYSE:VAR, XSWX:SOON, OCSE:WDH, SZSE:300003, ASX:COH, XPAR:DIM, NZSE:FPH, LSE:CTEC, OCSE:GN, NYSE:GMED » details
Traded in other countries:MDT.Argentina, MDTC34.Brazil, 2M6.Germany, MDTN.Mexico, MDT.Switzerland, 0Y6X.UK,
Headquarter Location:Ireland
Medtronic PLC is a medical technology company. It primarily manufacture and sell device-based medical therapies. It operates in Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies and Diabetes segments.

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for about 45% of the company's total sales.

Guru Investment Theses on Medtronic PLC

Jeff Auxier Comments on Medtronic - Aug 03, 2017

Deeply oversold in 2016 political uncertainties, the world's largest standalone medical technology company rebounded sharply for the quarter. A leader in biomedical devices, they sold their medical supplies business for $6.1 billion and will pay down debt and repurchase shares.


From Jeff Auxier (Trades, Portfolio)'s second-quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Medtronic plc - May 09, 2017

Medtronic is a leader in implantable biomedical devices. Back in 2001 the stock traded at 37.5 times earnings and this past quarter traded down to 13 times earnings with a fortress balance sheet and a 7% free cash flow yield. They continue to be a leader in medical technology as their world’s smallest pacemaker, Micra, accelerates US sales driving pacemaker market growth. They generate over $5 billion in free cash flow annually.

From Jeff Auxier (Trades, Portfolio)'s Auxier Asset Management first quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Gabelli Funds Comments on Medtronic Plc - Aug 04, 2016

Medtronic plc (NYSE:MDT) (1.7%) (MDT – $75.00 – NYSE) cemented its position as the largest manufacturer of medical devices in the world with last year’s $50 billion acquisition of Covidien. This deal, structured as a tax inversion, should both improve the company’s growth rate and give it better access to its global cash flow. Meanwhile, Medtronic is accelerating its own growth rate through improved management execution and a full pipeline of new heart valves, drug coated balloons, and defibrillators. Medtronic will be the partner of choice for hospitals going forward, and the Covidien deal will allow the company to continue to return at least 50% of its cash flow to shareholders via share buybacks and dividends.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Medtronic PLC

ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement
Study Shows Positive Results with Medtronic Cryoballoon for Patients with Persistent Atrial Fibrillation
Clinical Trials Show Strong Long-Term Performance with the Medtronic CoreValve TAVR System
Steven Cohen Takes Stake in Biotech Company Agenus Guru expands position in health care space
Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed this week he established a 6.13% stake in Agenus Inc. (NASDAQ:AGEN) on Feb. 21. Read more...
Medtronic Chairman and CEO Omar Ishrak to Speak at CEO Investor Forum 3.0
Report: Exploring Fundamental Drivers Behind John B. Sanfilippo & Son, Spero Therapeutics, Live Oak Bancshares, Medtronic, Automatic Data Processing, and Enphase Energy — New Horizons, Emerging Trends, and Upcoming Developments
Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region
Medtronic and Philips Partner to Innovate in Lung Cancer Management
Medtronic Launches IDE Study to Evaluate the Abre(TM) Venous Self-Expanding Stent System in Patients with Deep Venous Disease
Medtronic Receives FDA Clearance for Riptide(TM) Aspiration System

Ratios

vs
industry
vs
history
PE Ratio 39.42
MDT's PE Ratio is ranked lower than
66% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. MDT: 39.42 )
Ranked among companies with meaningful PE Ratio only.
MDT' s PE Ratio Range Over the Past 10 Years
Min: 10.17  Med: 21.05 Max: 54.09
Current: 39.42
10.17
54.09
Forward PE Ratio 15.50
MDT's Forward PE Ratio is ranked higher than
85% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. MDT: 15.50 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 39.42
MDT's PE Ratio without NRI is ranked lower than
65% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. MDT: 39.42 )
Ranked among companies with meaningful PE Ratio without NRI only.
MDT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.17  Med: 21.05 Max: 54.09
Current: 39.42
10.17
54.09
Price-to-Owner-Earnings 22.83
MDT's Price-to-Owner-Earnings is ranked higher than
64% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 32.03 vs. MDT: 22.83 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MDT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.24  Med: 18.91 Max: 37.87
Current: 22.83
9.24
37.87
PB Ratio 2.16
MDT's PB Ratio is ranked higher than
62% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. MDT: 2.16 )
Ranked among companies with meaningful PB Ratio only.
MDT' s PB Ratio Range Over the Past 10 Years
Min: 1.78  Med: 2.63 Max: 5.76
Current: 2.16
1.78
5.76
PS Ratio 3.69
MDT's PS Ratio is ranked lower than
55% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. MDT: 3.69 )
Ranked among companies with meaningful PS Ratio only.
MDT' s PS Ratio Range Over the Past 10 Years
Min: 1.92  Med: 3.51 Max: 5.23
Current: 3.69
1.92
5.23
Price-to-Free-Cash-Flow 25.36
MDT's Price-to-Free-Cash-Flow is ranked higher than
52% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.44 vs. MDT: 25.36 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MDT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.18  Med: 14.41 Max: 29.26
Current: 25.36
9.18
29.26
Price-to-Operating-Cash-Flow 20.20
MDT's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 20.01 vs. MDT: 20.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MDT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.13  Med: 12.61 Max: 23.4
Current: 20.2
8.13
23.4
EV-to-EBIT 18.90
MDT's EV-to-EBIT is ranked higher than
59% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. MDT: 18.90 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.2  Med: 15.2 Max: 31.1
Current: 18.9
7.2
31.1
EV-to-EBITDA 13.36
MDT's EV-to-EBITDA is ranked higher than
61% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. MDT: 13.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3  Med: 12.7 Max: 23.6
Current: 13.36
6.3
23.6
EV-to-Revenue 4.14
MDT's EV-to-Revenue is ranked lower than
57% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. MDT: 4.14 )
Ranked among companies with meaningful EV-to-Revenue only.
MDT' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.3  Med: 3.5 Max: 6.4
Current: 4.14
2.3
6.4
PEG Ratio 9.61
MDT's PEG Ratio is ranked lower than
84% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. MDT: 9.61 )
Ranked among companies with meaningful PEG Ratio only.
MDT' s PEG Ratio Range Over the Past 10 Years
Min: 1.04  Med: 2.73 Max: 25.64
Current: 9.61
1.04
25.64
Shiller PE Ratio 27.26
MDT's Shiller PE Ratio is ranked higher than
74% of the 58 Companies
in the Global Medical Devices industry.

( Industry Median: 49.95 vs. MDT: 27.26 )
Ranked among companies with meaningful Shiller PE Ratio only.
MDT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.49  Med: 23.05 Max: 39.84
Current: 27.26
14.49
39.84
Current Ratio 2.43
MDT's Current Ratio is ranked lower than
52% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. MDT: 2.43 )
Ranked among companies with meaningful Current Ratio only.
MDT' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.38 Max: 6.8
Current: 2.43
0.88
6.8
Quick Ratio 2.09
MDT's Quick Ratio is ranked higher than
52% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. MDT: 2.09 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.87 Max: 6.46
Current: 2.09
0.66
6.46
Days Inventory 144.34
MDT's Days Inventory is ranked lower than
51% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. MDT: 144.34 )
Ranked among companies with meaningful Days Inventory only.
MDT' s Days Inventory Range Over the Past 10 Years
Min: 132.14  Med: 142.57 Max: 164.01
Current: 144.34
132.14
164.01
Days Sales Outstanding 70.91
MDT's Days Sales Outstanding is ranked lower than
53% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. MDT: 70.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.69  Med: 81.9 Max: 92.09
Current: 70.91
68.69
92.09
Days Payable 72.59
MDT's Days Payable is ranked higher than
59% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. MDT: 72.59 )
Ranked among companies with meaningful Days Payable only.
MDT' s Days Payable Range Over the Past 10 Years
Min: 39.63  Med: 54.03 Max: 93.14
Current: 72.59
39.63
93.14

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.30
MDT's Dividend Yield % is ranked higher than
83% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 1.12 vs. MDT: 2.30 )
Ranked among companies with meaningful Dividend Yield % only.
MDT' s Dividend Yield % Range Over the Past 10 Years
Min: 0.8  Med: 2 Max: 2.93
Current: 2.3
0.8
2.93
Dividend Payout Ratio 0.89
MDT's Dividend Payout Ratio is ranked higher than
71% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 0.32 vs. MDT: 0.89 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MDT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.35 Max: 0.89
Current: 0.89
0.26
0.89
3-Year Dividend Growth Rate 15.40
MDT's 3-Year Dividend Growth Rate is ranked higher than
64% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 9.70 vs. MDT: 15.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MDT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 7.6  Med: 16.7 Max: 30.2
Current: 15.4
7.6
30.2
Forward Dividend Yield % 2.30
MDT's Forward Dividend Yield % is ranked higher than
82% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.48 vs. MDT: 2.30 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.13
MDT's 5-Year Yield-on-Cost % is ranked higher than
84% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. MDT: 4.13 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MDT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.44  Med: 3.57 Max: 5.26
Current: 4.13
1.44
5.26
3-Year Average Share Buyback Ratio -11.10
MDT's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. MDT: -11.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.3  Med: -0.2 Max: 2.5
Current: -11.1
-11.3
2.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.20
MDT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
84% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. MDT: 1.20 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MDT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.79  Med: 1.97 Max: 9.69
Current: 1.2
0.79
9.69
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.68
MDT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
85% of the 27 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. MDT: 3.68 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
MDT' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.54  Med: 1.52 Max: 4.69
Current: 3.68
0.54
4.69
Price-to-Median-PS-Value 1.04
MDT's Price-to-Median-PS-Value is ranked lower than
54% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. MDT: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MDT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.42  Med: 1.15 Max: 4.27
Current: 1.04
0.42
4.27
Price-to-Peter-Lynch-Fair-Value 7.43
MDT's Price-to-Peter-Lynch-Fair-Value is ranked lower than
94% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. MDT: 7.43 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MDT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.86  Med: 2.12 Max: 7.98
Current: 7.43
0.86
7.98
Earnings Yield (Greenblatt) % 5.29
MDT's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. MDT: 5.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MDT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.2  Med: 6.6 Max: 13.9
Current: 5.29
3.2
13.9
Forward Rate of Return (Yacktman) % 10.02
MDT's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. MDT: 10.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MDT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 6.6  Med: 11.8 Max: 17.7
Current: 10.02
6.6
17.7

More Statistics

Revenue (TTM) (Mil) $29,725.00
EPS (TTM) $ 2.03
Beta0.74
Volatility14.62%
52-Week Range $76.41 - 89.72
Shares Outstanding (Mil)1,355.37

Analyst Estimate

Apr18 Apr19 Apr20
Revenue (Mil $) 29,529 30,589 32,794
EBIT (Mil $) 6,119 6,982 8,221
EBITDA (Mil $) 9,130 10,035 11,386
EPS ($) 4.73 5.19 5.99
EPS without NRI ($) 4.73 5.19 5.99
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.42%
Dividends per Share ($) 1.89 2.09 2.37

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}